104
Participants
Start Date
June 14, 2016
Primary Completion Date
February 25, 2020
Study Completion Date
February 25, 2020
Ribociclib
supplied in 50 mg, 200 mg capsules/tablets taken orally and dosed daily for 28 day cycle
Everolimus
supplied in 2.5 mg tablets taken orally, daily for 28 day cycle
Exemestane
supplied in 25 mg tablets taken orally, daily for 28 day cycle
Penn State Hershey Cancer Institute, Hershey
University of Pennsylvania Medical Center Abramson Cancer Ctr of the Uni, Philadelphia
UF Health Cancer Center at Orlando Health UF Health (4), Orlando
Florida Cancer Research Institute Dept of Oncology, Davie
Florida Cancer Specialists-North, St. Petersburg
Florida Cancer Specialists FL Cancer Specialists, Fort Myers
Sarah Cannon Research Institute Sarah Cannon Research Insti, Nashville
Henry Ford Health System, Detroit
Washington University School of Medicine Washington U School of Medicin, St Louis
St. Luke's Cancer Institute Regulatory, Kansas City
Research Medical Center HCA Midwest Division, Kansas City
University of Kansas Cancer Center Univ of KS CC Medical Pavilion, Westwood
Highlands Oncology Group, Fayetteville
Oncology Consultants Oncology Consultants, Houston
MD Anderson Cancer Center/University of Texas MDACC, Houston
Huntsman Cancer Institute Huntsman Cancer Insti, Salt Lake City
Ironwood Cancer and Research Centers Ironwood Cancer, Chandler
UCLA Department of Medicine UCLA Hematology/Oncology, Los Angeles
Central Coast Medical Oncology Corporation Onc Dept, Santa Maria
University of California San Francisco Comprehensive Cancer Center, San Francisco
Northwest Medical Specialties Dept of Onc, Tacoma
Yale University School of Medicine Smilow Cancer Hospital, New Haven
Atlanta Cancer Center, Atlanta
Massachusetts General Hospital Mass Gen Hos Cancer Center, Boston
Saint Barnabas Medical Center, Livingston
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY